Covered recipient · General Payments record
BRADLEY LAWRENCE FREILICH
Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$2,483.13
59 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,233.13 | 57 |
| Honoraria | $750.00 | 1 |
| Consulting Fee | $500.00 | 1 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Endogastric Solutions, Inc | $817.26 | 3 |
| Intercept Pharmaceuticals, Inc. | $792.38 | 4 |
| Novo Nordisk Inc | $191.04 | 7 |
| AbbVie Inc. | $170.19 | 12 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $163.34 | 12 |
| Takeda Pharmaceuticals U.S.A., Inc. | $74.85 | 4 |
| Janssen Biotech, Inc. | $61.12 | 4 |
| Amgen Inc. | $48.46 | 2 |
| Medtronic, Inc. | $39.67 | 3 |
| Gilead Sciences, Inc. | $21.51 | 1 |
| Nestle HealthCare Nutrition Inc. | $21.21 | 1 |
| Lilly USA, LLC | $17.77 | 1 |
| Merck Sharp & Dohme Corporation | $16.09 | 1 |
| Celgene Corporation | $12.86 | 1 |
| PFIZER INC. | $12.37 | 1 |
| Ironwood Pharmaceuticals, Inc | $11.71 | 1 |
| Currax Pharmaceuticals LLC | $11.30 | 1 |
Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
BRADLEY LAWRENCE FREILICH
NPI 1659424810 · CMS profile ID 29968
Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology
KANSAS CITY, MO
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1659424810?year=2021&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- BRADLEY LAWRENCE FREILICH, NPI 1659424810, CMS profile ID 29968. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1659424810?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). BRADLEY LAWRENCE FREILICH, NPI 1659424810, CMS profile ID 29968. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1659424810?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- BRADLEY LAWRENCE FREILICH, NPI 1659424810, CMS profile ID 29968, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1659424810?year=2021&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
59 matching records · $2,483.13 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–59 of 59.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Novo Nordisk Inc | $10.55 | 02/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811289775 | CMS |
| Novo Nordisk Inc | $4.45 | 02/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 810927977 | CMS |
| Nestle HealthCare Nutrition Inc. | $21.21 | 02/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 820896549 | CMS |
| AbbVie Inc. | $13.28 | 02/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794513967 | CMS |
| Janssen Biotech, Inc. | $15.34 | 02/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788531189 | CMS |
| AbbVie Inc. | $12.30 | 01/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794513963 | CMS |
| Intercept Pharmaceuticals, Inc. | $750.00 | 01/20/2021 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 836206151 | CMS |
| Ironwood Pharmaceuticals, Inc | $11.71 | 01/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 855121821 | CMS |
| Intercept Pharmaceuticals, Inc. | $10.12 | 01/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 836206149 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,244,964.12 | 299 |
| PY2024 | Recipient | $4,186.63 | 2 |
| PY2024 | Principal investigator | $704,281.35 | 220 |
| PY2023 | Recipient | $1,257.17 | 1 |
| PY2023 | Principal investigator | $575,605.58 | 68 |
| PY2022 | Principal investigator | $481,663.25 | 45 |
| PY2021 | Principal investigator | $439,962.90 | 230 |
| PY2020 | Principal investigator | $314,704.54 | 55 |
| PY2019 | Principal investigator | $693,990.66 | 77 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
299 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Tanabe Pharma America, Inc. | $70.00 | 12/31/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) | No dispute reported | 06/30/2026 | 1243870475 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $754.73 | 12/22/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654304 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $754.73 | 12/22/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654316 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,565.22 | 12/19/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248254311 |
| Principal investigator 1 | Tanabe Pharma America, Inc. | $2,176.20 | 12/19/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability ofMT-7117in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria | No dispute reported | 06/30/2026 | 1243870381 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291696 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291698 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291700 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291702 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291706 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291708 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291710 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291712 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291714 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291716 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291718 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291720 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291722 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291724 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291726 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291728 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291730 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291732 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291734 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291736 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291738 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291740 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291742 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291744 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291746 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291748 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291750 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291752 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291754 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291756 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291758 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291760 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291762 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291764 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291766 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291768 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291770 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291772 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291774 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291776 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291778 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291780 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291782 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291784 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291786 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291788 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291790 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291792 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291794 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291796 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291798 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291800 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291802 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291804 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291806 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291808 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291810 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291830 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291832 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291834 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291836 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291838 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291840 |
| Principal investigator 1 | Seqirus USA Inc | $847.00 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291842 |
| Principal investigator 1 | Seqirus USA Inc | $422.80 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291844 |
| Principal investigator 1 | Seqirus USA Inc | $422.80 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291846 |
| Principal investigator 1 | Seqirus USA Inc | $422.80 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291848 |
| Principal investigator 1 | Seqirus USA Inc | $422.80 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291850 |
| Principal investigator 1 | Seqirus USA Inc | $422.80 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291852 |
| Principal investigator 1 | Seqirus USA Inc | $422.80 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291858 |
| Principal investigator 1 | Seqirus USA Inc | $847.00 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291860 |
| Principal investigator 1 | Seqirus USA Inc | $1,108.80 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291865 |
| Principal investigator 1 | Seqirus USA Inc | $1,162.00 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291868 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291878 |
| Principal investigator 1 | Seqirus USA Inc | $1,108.80 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291934 |
| Principal investigator 1 | Seqirus USA Inc | $1,108.80 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291936 |
| Principal investigator 1 | Seqirus USA Inc | $1,108.80 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291938 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291940 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291942 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291944 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291946 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291948 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291950 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291952 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291954 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291956 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291958 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291960 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291962 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291964 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291966 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291968 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291970 |
| Principal investigator 1 | Seqirus USA Inc | $3,204.60 | 12/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291972 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $139.92 | 12/17/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654336 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $479.52 | 12/17/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654338 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,460.00 | 12/17/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654340 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8.00 | 12/17/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654342 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $375.00 | 12/17/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220654362 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $46.64 | 12/17/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220654366 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $439.56 | 12/17/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220654368 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $584.00 | 12/17/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220654370 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8.00 | 12/17/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220654372 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $10,001.60 | 12/11/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248253842 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $11,664.00 | 12/05/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248253566 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.76 | 12/03/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654288 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $99.40 | 12/03/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654290 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,400.00 | 12/03/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654292 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $71.00 | 12/03/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654294 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $170.40 | 12/03/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654296 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $134.90 | 12/03/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654298 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $170.40 | 12/03/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654300 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $106.50 | 12/03/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654302 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $170.40 | 12/03/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654306 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $284.00 | 12/03/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654308 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $92.30 | 12/03/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654310 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $134.90 | 12/03/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654312 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $106.50 | 12/03/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654314 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $170.40 | 12/03/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654318 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,973.77 | 12/03/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654320 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $170.40 | 12/03/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654322 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $284.00 | 12/03/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654324 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $170.40 | 12/03/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654326 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $99.40 | 12/03/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654328 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,604.52 | 12/03/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220654364 |
| Principal investigator 1 | Seqirus USA Inc | $4,701.40 | 12/01/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age | No dispute reported | 06/30/2026 | 1250810394 |
| Principal investigator 1 | Seqirus USA Inc | $1,291.95 | 12/01/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age | No dispute reported | 06/30/2026 | 1250810403 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $754.73 | 11/27/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654278 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,578.72 | 11/27/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654280 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $754.73 | 11/27/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654282 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,687.74 | 11/27/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654284 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $13,467.28 | 11/27/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654286 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $700.00 | 11/27/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220654360 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $16,631.64 | 11/25/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248252870 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $6,194.46 | 11/07/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248252420 |
| Principal investigator 1 | Seqirus USA Inc | $3,846.60 | 11/03/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age | No dispute reported | 06/30/2026 | 1250810381 |
| Principal investigator 1 | Seqirus USA Inc | $1,057.05 | 11/03/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age | No dispute reported | 06/30/2026 | 1250810388 |
| Principal investigator 1 | Tanabe Pharma America, Inc. | $70.00 | 11/01/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) | No dispute reported | 06/30/2026 | 1243870483 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,400.00 | 10/29/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654272 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,687.74 | 10/27/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654268 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,687.74 | 10/27/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654270 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $13,467.28 | 10/27/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654274 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $754.73 | 10/27/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654276 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.96 | 10/27/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654330 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $182.50 | 10/27/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654332 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.00 | 10/27/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654334 |
| Principal investigator 1 | Seqirus USA Inc | $1,500.00 | 10/27/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291870 |
| Principal investigator 1 | Seqirus USA Inc | $2,000.00 | 10/27/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291872 |
| Principal investigator 1 | Seqirus USA Inc | $2,500.00 | 10/27/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291874 |
| Principal investigator 1 | Seqirus USA Inc | $3,000.00 | 10/27/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291876 |
| Principal investigator 1 | Seqirus USA Inc | $12,000.00 | 10/27/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291880 |
| Principal investigator 1 | Seqirus USA Inc | $2,000.00 | 10/27/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291930 |
| Principal investigator 1 | Seqirus USA Inc | $2,000.00 | 10/27/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291932 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $900.00 | 10/23/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248251799 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $70,245.00 | 10/23/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248251803 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $3,350.00 | 10/23/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248251807 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,100.00 | 10/23/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248251811 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $5,000.80 | 10/23/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248251816 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,421.00 | 10/21/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229207078 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,064.82 | 10/16/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248251521 |
| Principal investigator 1 | Gilead Sciences, Inc. | $3,310.32 | 10/14/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229207067 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,500.40 | 10/09/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248251419 |
| Principal investigator 1 | Tanabe Pharma America, Inc. | $3,573.93 | 10/09/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) | No dispute reported | 06/30/2026 | 1243870399 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,500.40 | 10/03/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248251005 |
| Principal investigator 1 | Tanabe Pharma America, Inc. | $70.00 | 10/01/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) | No dispute reported | 06/30/2026 | 1243870485 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $13,467.28 | 09/26/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654266 |
| Principal investigator 1 | Bausch Health US, LLC | $2,272.82 | 09/24/2025 | Non-covered Recipient Entity Kansas City Research LLC | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224842247 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $365.00 | 09/24/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654262 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.00 | 09/24/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654264 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,129.64 | 09/18/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248250225 |
| Principal investigator 1 | Seqirus USA Inc | $110.98 | 09/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291854 |
| Principal investigator 1 | Seqirus USA Inc | $111.30 | 09/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291856 |
| Principal investigator 1 | Seqirus USA Inc | $946.80 | 09/18/2025 | Non-covered Recipient Entity Kansas City Research Institute LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185291862 |
| Principal investigator 1 | Gilead Sciences, Inc. | $7,954.13 | 09/16/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229207059 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,064.82 | 09/12/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248249900 |
| Principal investigator 1 | Bausch Health US, LLC | $2,009.70 | 09/11/2025 | Non-covered Recipient Entity Kansas City Research LLC | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224842250 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $506.25 | 09/04/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248249508 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $135.00 | 09/04/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248249511 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,500.40 | 09/04/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248249515 |
| Principal investigator 1 | Tanabe Pharma America, Inc. | $140.00 | 09/04/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability ofMT-7117in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria | No dispute reported | 06/30/2026 | 1243870401 |
| Principal investigator 1 | Tanabe Pharma America, Inc. | $500.00 | 09/04/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability ofMT-7117in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria | No dispute reported | 06/30/2026 | 1243870403 |
| Principal investigator 1 | Gilead Sciences, Inc. | $975.66 | 09/02/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229207048 |
| Principal investigator 1 | Tanabe Pharma America, Inc. | $70.00 | 09/01/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) | No dispute reported | 06/30/2026 | 1243870487 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $182.50 | 08/26/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654258 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $504.40 | 08/26/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654260 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 08/26/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220654358 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,129.64 | 08/26/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248249082 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,064.82 | 08/21/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248248866 |
| Principal investigator 1 | Tanabe Pharma America, Inc. | $2,360.70 | 08/21/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability ofMT-7117in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria | No dispute reported | 06/30/2026 | 1243870379 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,500.40 | 08/14/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248248412 |
| Principal investigator 1 | Bausch Health US, LLC | $2,031.12 | 08/08/2025 | Non-covered Recipient Entity Kansas City Research LLC | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224842255 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,064.82 | 08/07/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248248115 |
| Principal investigator 1 | Tanabe Pharma America, Inc. | $70.00 | 08/01/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) | No dispute reported | 06/30/2026 | 1243870473 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $40,941.00 | 07/31/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248247741 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,100.00 | 07/31/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248247745 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $16,007.62 | 07/31/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248247749 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,500.40 | 07/31/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248247753 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $255.50 | 07/28/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654256 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $59.94 | 07/28/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220654354 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.00 | 07/28/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220654356 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $6,194.46 | 07/22/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248247398 |
| Principal investigator 1 | Tanabe Pharma America, Inc. | $37.66 | 07/22/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) | No dispute reported | 06/30/2026 | 1243870385 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,500.40 | 07/17/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248247143 |
| Principal investigator 1 | Bausch Health US, LLC | $2,320.29 | 07/09/2025 | Non-covered Recipient Entity Kansas City Research LLC | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224842243 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,356.00 | 07/08/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248246658 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $607.50 | 07/08/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248246661 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $708.75 | 07/08/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248246666 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,821.75 | 07/08/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248246670 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $506.25 | 07/07/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248246600 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $14,227.50 | 07/07/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248246605 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,000.00 | 07/07/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248246609 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,950.00 | 07/07/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248246613 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,500.00 | 07/07/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248246617 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,500.00 | 07/07/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248246621 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,064.82 | 07/04/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248246473 |
| Principal investigator 1 | Tanabe Pharma America, Inc. | $500.00 | 07/04/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability ofMT-7117in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria | No dispute reported | 06/30/2026 | 1243870383 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $19,743.00 | 07/01/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248246239 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $810.00 | 07/01/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248246243 |
| Principal investigator 1 | Tanabe Pharma America, Inc. | $70.00 | 07/01/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) | No dispute reported | 06/30/2026 | 1243870477 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.96 | 06/24/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654252 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.00 | 06/24/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654254 |
| Principal investigator 1 | Tanabe Pharma America, Inc. | $500.00 | 06/24/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability ofMT-7117in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria | No dispute reported | 06/30/2026 | 1243870387 |
| Principal investigator 1 | Tanabe Pharma America, Inc. | $280.00 | 06/24/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability ofMT-7117in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria | No dispute reported | 06/30/2026 | 1243870389 |
| Principal investigator 1 | Tanabe Pharma America, Inc. | $300.00 | 06/24/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) | No dispute reported | 06/30/2026 | 1243870391 |
| Principal investigator 1 | Tanabe Pharma America, Inc. | $427.95 | 06/24/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) | No dispute reported | 06/30/2026 | 1243870393 |
| Principal investigator 1 | Tanabe Pharma America, Inc. | $27.00 | 06/24/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) | No dispute reported | 06/30/2026 | 1243870395 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $37,800.00 | 06/19/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248245766 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $809.25 | 06/19/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248245770 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,500.40 | 06/19/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248245774 |
| Principal investigator 1 | Gilead Sciences, Inc. | $5,619.00 | 06/17/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229207040 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,428.67 | 06/12/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248245235 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $7,687.40 | 06/12/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248245239 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,500.00 | 06/10/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229207034 |
| Principal investigator 1 | Bausch Health US, LLC | $5,744.34 | 06/05/2025 | Non-covered Recipient Entity Kansas City Research LLC | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224842283 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,500.40 | 06/05/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248244841 |
| Principal investigator 1 | Gilead Sciences, Inc. | $2,075.00 | 06/03/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229207011 |
| Principal investigator 1 | Gilead Sciences, Inc. | $3,500.00 | 06/03/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229207021 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,208.96 | 06/03/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229207028 |
| Principal investigator 1 | Tanabe Pharma America, Inc. | $70.00 | 06/01/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) | No dispute reported | 06/30/2026 | 1243870479 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $9,938.42 | 05/28/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248244526 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.96 | 05/27/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654248 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $146.00 | 05/27/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654250 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,565.22 | 05/22/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248244087 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $23,471.16 | 05/15/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248243480 |
| Principal investigator 1 | Tanabe Pharma America, Inc. | $2,264.40 | 05/15/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability ofMT-7117in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria | No dispute reported | 06/30/2026 | 1243870397 |
| Principal investigator 1 | Bausch Health US, LLC | $4,588.29 | 05/07/2025 | Non-covered Recipient Entity Kansas City Research LLC | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224842275 |
| Principal investigator 1 | Tanabe Pharma America, Inc. | $70.00 | 05/01/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) | No dispute reported | 06/30/2026 | 1243870481 |
| Principal investigator 1 | Gilead Sciences, Inc. | $3,849.00 | 04/22/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229207003 |
| Principal investigator 1 | Tanabe Pharma America, Inc. | $3,500.00 | 04/15/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability ofMT-7117in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria | No dispute reported | 06/30/2026 | 1243870375 |
| Principal investigator 1 | Tanabe Pharma America, Inc. | $1,000.00 | 04/15/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability ofMT-7117in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria | No dispute reported | 06/30/2026 | 1243870377 |
| Principal investigator 1 | Tanabe Pharma America, Inc. | $1,172.47 | 04/08/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) | No dispute reported | 06/30/2026 | 1243870373 |
| Principal investigator 1 | Bausch Health US, LLC | $4,595.85 | 04/01/2025 | Non-covered Recipient Entity Kansas City Research LLC | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224842278 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $9,592.42 | 04/01/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248241519 |
| Principal investigator 1 | Tanabe Pharma America, Inc. | $70.00 | 04/01/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) | No dispute reported | 06/30/2026 | 1243870471 |
| Principal investigator 1 | Gilead Sciences, Inc. | $13,738.00 | 03/18/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229206995 |
| Principal investigator 1 | Bausch Health US, LLC | $3,206.76 | 03/11/2025 | Non-covered Recipient Entity Kansas City Research LLC | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224842266 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $115,354.00 | 03/06/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248240408 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $29,935.63 | 03/06/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248240412 |
| Principal investigator 1 | Bausch Health US, LLC | $105.00 | 03/05/2025 | Non-covered Recipient Entity Kansas City Research LLC | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224842264 |
| Principal investigator 1 | Tanabe Pharma America, Inc. | $70.00 | 03/01/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) | No dispute reported | 06/30/2026 | 1243870493 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $209.88 | 02/25/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654238 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $139.86 | 02/25/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654240 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $730.00 | 02/25/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654242 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $58.62 | 02/25/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654244 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6.00 | 02/25/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654246 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $98,260.00 | 02/20/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248239909 |
| Principal investigator 1 | Gilead Sciences, Inc. | $11,140.00 | 02/19/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229206988 |
| Principal investigator 1 | Tanabe Pharma America, Inc. | $2,264.40 | 02/18/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability ofMT-7117in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria | No dispute reported | 06/30/2026 | 1243870409 |
| Principal investigator 1 | Tanabe Pharma America, Inc. | $648.00 | 02/18/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) | No dispute reported | 06/30/2026 | 1243870411 |
| Principal investigator 1 | Tanabe Pharma America, Inc. | $54.00 | 02/18/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) | No dispute reported | 06/30/2026 | 1243870413 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $5,473.57 | 02/07/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248239589 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $26,443.70 | 02/06/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248239250 |
| Principal investigator 1 | Tanabe Pharma America, Inc. | $70.00 | 02/01/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) | No dispute reported | 06/30/2026 | 1243870491 |
| Principal investigator 1 | Bausch Health US, LLC | $2,509.29 | 01/28/2025 | Non-covered Recipient Entity Kansas City Research LLC | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224842260 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $479.78 | 01/28/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654222 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.04 | 01/28/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654224 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9.00 | 01/28/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654226 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $42.86 | 01/28/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654228 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6.74 | 01/28/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654230 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $25.72 | 01/28/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654232 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.28 | 01/28/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654234 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9.00 | 01/28/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220654236 |
| Principal investigator 1 | Eli Lilly and Company | $87,022.00 | 01/28/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) | No dispute reported | 06/30/2026 | 1187885820 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $209.88 | 01/27/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220654344 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $139.86 | 01/27/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220654346 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $730.00 | 01/27/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220654348 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $58.62 | 01/27/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220654350 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6.00 | 01/27/2025 | Non-covered Recipient Entity Kansas City Gastroenterology And Hepatology Physicians Group LLC | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220654352 |
| Principal investigator 1 | Tanabe Pharma America, Inc. | $2,264.40 | 01/17/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability ofMT-7117in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria | No dispute reported | 06/30/2026 | 1243870407 |
| Principal investigator 1 | Eli Lilly and Company | $1,329.37 | 01/15/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) | No dispute reported | 06/30/2026 | 1187884300 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,354.72 | 01/10/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248238367 |
| Principal investigator 1 | Bausch Health US, LLC | $1,961.82 | 01/07/2025 | Non-covered Recipient Entity Kansas City Research LLC | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224842271 |
| Principal investigator 1 | Tanabe Pharma America, Inc. | $1,586.79 | 01/07/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) | No dispute reported | 06/30/2026 | 1243870405 |
| Principal investigator 1 | Tanabe Pharma America, Inc. | $70.00 | 01/01/2025 | Non-covered Recipient Entity KANSAS CITY RESEARCH INSTITUTE LLC | A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) | No dispute reported | 06/30/2026 | 1243870489 |